{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:11:55Z","timestamp":1792685515368,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010699","name":"Monash University Malaysia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010699","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.critrevonc.2026.105188","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T16:27:23Z","timestamp":1770481643000},"page":"105188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Therapeutic potential of MicroRNAs in targeting breast cancer stem cells: A systematic review"],"prefix":"10.1016","volume":"221","author":[{"given":"Joyce Zhin Shi","family":"Ting","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelyn","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany Yan Yue","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi Mynn","family":"Yeoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy Wai Yeng","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1685-1814","authenticated-orcid":false,"given":"Han Yin","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.critrevonc.2026.105188_bib1","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.bbrc.2011.07.033","article-title":"ErbB2 down-regulates microRNA-205 in breast cancer","volume":"411","author":"Adachi","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105188_bib2","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1158\/0008-5472.CAN-15-2321","article-title":"MIR-34A silences C-SRC to attenuate tumor growth in Triple-Negative Breast Cancer","volume":"76","author":"Adams","year":"2016","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105188_bib3","doi-asserted-by":"crossref","first-page":"14759","DOI":"10.1002\/jcp.28271","article-title":"Current approaches in identification and isolation of cancer stem cells","volume":"234","author":"Akbarzadeh","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105188_bib4","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1073\/pnas.0530291100","article-title":"Prospective identification of tumorigenic breast cancer cells","volume":"100","author":"Al-Hajj","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.critrevonc.2026.105188_bib5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","article-title":"Current and future burden of breast cancer: Global statistics for 2020 and 2040","volume":"66","author":"Arnold","year":"2022","journal-title":"Breast (Ediniburgh Scotl. )"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105188_bib6","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.3390\/pharmaceutics15051439","article-title":"Therapeutic and Diagnostic Potential of Exosomes as Drug Delivery Systems in Brain Cancer","volume":"15","author":"Avgoulas","year":"2023","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105188_bib7","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/15384101.2022.2035915","article-title":"Effects of noncoding RNAs in radiotherapy response in breast cancer: a systematic review","volume":"21","author":"Bakhshaiesh","year":"2022","journal-title":"Cell Cycle"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105188_bib8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae \u2014 The first FDA-approved nano-drug: Lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105188_bib9","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.4155\/fmc.14.116","article-title":"miRNA-based therapies: Strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents","volume":"6","author":"Baumann","year":"2014","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.critrevonc.2026.105188_bib10","doi-asserted-by":"crossref","unstructured":"Chen, F., Luo, N., Hu, Y., Li, X., & Zhang https:\/\/doi.org\/10.1038\/cddis.2015.192, K. (2018). MiR-137 suppresses triple negative breast cancer stemness and tumorigenesis by perturbing BCL11A DNMT1 interaction. Cellular Physiology and Biochemistry, 47(5), 2147\u20132158. https:\/\/doi.org\/10.1159\/000491526.","DOI":"10.1159\/000491526"},{"key":"10.1016\/j.critrevonc.2026.105188_bib11","doi-asserted-by":"crossref","first-page":"76057","DOI":"10.18632\/oncotarget.18648","article-title":"Hinokitiol up-regulates miR-494-3p to suppress BMI1 expression and inhibits self-renewal of breast cancer stem\/progenitor cells","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105188_bib12","doi-asserted-by":"crossref","first-page":"7353","DOI":"10.1111\/jcmm.15317","article-title":"microRNA-128-3p overexpression inhibits breast cancer stem cell characteristics through suppression of Wnt signalling pathway by down-regulating NEK2","volume":"24","author":"Chen","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.critrevonc.2026.105188_bib13","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/s41419-018-0854-9","article-title":"MiR-205-5p inhibition by locked nucleic acids impairs metastatic potential of breast cancer cells","volume":"9","author":"De Cola","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.critrevonc.2026.105188_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.192","article-title":"miR-205-5p-mediated downregulation of ErbB\/HER receptors in breast cancer stem cells results in targeted therapy resistance","volume":"6","author":"De Cola","year":"2015","journal-title":"Cell Death Dis."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105188_bib15","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1089\/omi.2019.0147","article-title":"Targeting the Versatile Wnt\/\u03b2-Catenin Pathway in Cancer Biology and Therapeutics: From Concept to Actionable Strategy","volume":"23","author":"Dzobo","year":"2019","journal-title":"Omics a J. Integr. Biol."},{"key":"10.1016\/j.critrevonc.2026.105188_bib16","article-title":"The impact of microRNAs on the resistance of breast cancer subtypes to chemotherapy","volume":"249","author":"Ebrahimi","year":"2023","journal-title":"Pathol. Res Pr."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105188_bib17","first-page":"96","article-title":"Triple-negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Markers with Anti-miRNA: A Systematic Review and Meta-Analysis","volume":"5","author":"Fathi","year":"2023","journal-title":"Int. J. Sci. Res. Dent. Med. Sci."},{"key":"10.1016\/j.critrevonc.2026.105188_bib18","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ebiom.2019.02.034","article-title":"MiR-873\/PD-L1 axis regulates the stemness of breast cancer cells","volume":"41","author":"Gao","year":"2019","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105188_bib19","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","article-title":"Insights into molecular classifications of triple-negative breast cancer: Improving patient selection for treatment","volume":"9","author":"Garrido-Castro","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105188_bib20","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.biopha.2016.03.024","article-title":"MicroR-760 suppresses cancer stem cell subpopulation and breast cancer cell proliferation and metastasis: By down-regulating NANOG","volume":"80","author":"Han","year":"2016","journal-title":"Biomed. Pharmacother."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105188_bib21","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.2174\/1389201021666200420101613","article-title":"MicroRNA: Promising Roles in Cancer Therapy","volume":"21","author":"Hashemi","year":"2020","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.critrevonc.2026.105188_bib22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE\u2019s risk of bias tool for animal studies","volume":"14","author":"Hooijmans","year":"2014","journal-title":"BMC Med Res Method."},{"key":"10.1016\/j.critrevonc.2026.105188_bib23","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/S0960-9776(11)70297-1","article-title":"Breast cancer and microRNAs: therapeutic impact","volume":"20","author":"Iorio","year":"2011","journal-title":"Breast"},{"key":"10.1016\/j.critrevonc.2026.105188_bib24","unstructured":"Johnson, M., & Keyes, D. (2024, January 9). Anthracycline toxicity. StatPearls - NCBI Bookshelf. \u3008https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK599501\/\u3009."},{"key":"10.1016\/j.critrevonc.2026.105188_bib25","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.phrs.2015.04.015","article-title":"MicroRNA-based therapy and breast cancer: A comprehensive review of novel therapeutic strategies from diagnosis to treatment","volume":"97","author":"Kaboli","year":"2015","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105188_bib26","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.bbrc.2018.05.018","article-title":"MiR-130a-3p inhibits migration and invasion by regulating RAB5B in human breast cancer stem cell-like cells","volume":"501","author":"Kong","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105188_bib27","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.bbrc.2014.09.069","article-title":"Breast cancer stem cells, EMT and therapeutic targets","volume":"453","author":"Kotiyal","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105188_bib28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.32607\/20758251-2015-7-2-17-28","article-title":"Cancer Invasion: Patterns and Mechanisms","volume":"7","author":"Krakhmal","year":"2015","journal-title":"Acta Nat."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105188_bib29","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.21037\/atm-21-3241","article-title":"MiR-519d-5p modulates the sensitivity of breast cancer to chemotherapy by forming a negative feedback loop with RELA","volume":"9","author":"Li","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105188_bib30","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.omto.2020.06.002","article-title":"miR-7 reduces breast cancer stem cell metastasis via inhibiting RELA to decrease ESAM expression","volume":"4","author":"Li","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.critrevonc.2026.105188_bib31","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s12282-019-01002-0","article-title":"miR-638 represses the stem cell characteristics of breast cancer cells by targeting E2F2","volume":"27","author":"Lin","year":"2020","journal-title":"Breast Cancer"},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105188_bib32","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.7150\/thno.20771","article-title":"Nanoparticle delivery of miR-34a eradicates long-term-cultured breast cancer stem cells via targeting C22ORF28 directly","volume":"7","author":"Lin","year":"2017","journal-title":"Theranostics"},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105188_bib33","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.7150\/thno.29380","article-title":"miR-200c\/141 regulates breast cancer stem cell heterogeneity via targeting HIPK1\/\u03b2-Catenin axis","volume":"8","author":"Liu","year":"2018","journal-title":"Theranostics"},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105188_bib34","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1080\/15384101.2019.1638182","article-title":"MiR-124 reversed the doxorubicin resistance of breast cancer stem cells through STAT3\/HIF-1 signaling pathways","volume":"18","author":"Liu","year":"2019","journal-title":"Cell Cycle"},{"key":"10.1016\/j.critrevonc.2026.105188_bib35","article-title":"MiR-526b-3p attenuates breast cancer stem cell properties and chemoresistance by targeting HIF-2\u03b1\/Notch signaling","volume":"11","author":"Liu","year":"2021","journal-title":"Frontiers"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105188_bib36","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.stemcr.2013.11.009","article-title":"Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts","volume":"2","author":"Liu","year":"2013","journal-title":"Stem Cell Rep."},{"issue":"39","key":"10.1016\/j.critrevonc.2026.105188_bib37","doi-asserted-by":"crossref","first-page":"41638","DOI":"10.18632\/oncotarget.5873","article-title":"MicroRNA-1 down-regulates proliferation and migration of breast cancer stem cells by inhibiting the Wnt\/\u03b2 catenin pathway","volume":"6","author":"Liu","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105188_bib38","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s12015-019-09944-w","article-title":"Delivery of LNA-AntimiR-142-3p by mesenchymal stem Cells-Derived exosomes to breast cancer stem cells reduces tumorigenicity","volume":"16","author":"Naseri","year":"2020","journal-title":"Stem Cell Rev. Rep."},{"key":"10.1016\/j.critrevonc.2026.105188_bib39","series-title":"Stage 4 (IV) breast cancer: survival rates, treatment & prognosis","author":"National Breast Cancer Foundation","year":"2025"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105188_bib40","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/jcp.29059","article-title":"Inhibition of breast cancer growth via miR-7 suppressing ALDH1A3 activity concomitant with decreasing breast cancer stem cell subpopulation","volume":"235","author":"Pan","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105188_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.313","article-title":"Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53","volume":"6","author":"Park","year":"2015","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105188_bib42","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.18632\/oncotarget.2962","article-title":"Correction: By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy","volume":"6","author":"Petrelli","year":"2019","journal-title":"Oncotarget"},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105188_bib43","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/jnci\/djj495","article-title":"The response of CD24 \u2212\/low \/CD44 + breast cancer\u2013initiating cells to radiation","volume":"98","author":"Phillips","year":"2006","journal-title":"JNCI Journal National Cancer Institute"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105188_bib44","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejcb.2012.11.002","article-title":"MiR-205 in cancer: An angel or a devil?","volume":"92","author":"Qin","year":"2013","journal-title":"Eur. J. Cell Biol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105188_bib45","doi-asserted-by":"crossref","first-page":"507","DOI":"10.4161\/cc.10.3.14754","article-title":"MicroRNA expression analysis in triple-negative (ER, PR and Her2\/neu) breast cancer","volume":"10","author":"Radojicic","year":"2011","journal-title":"Cell Cycle"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105188_bib46","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s13287-022-02856-6","article-title":"Drug resistance in cancer therapy: the Pandora\u2019s Box of cancer stem cells","volume":"13","author":"Rezayatmand","year":"2022","journal-title":"Stem Cell Res. Ther."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105188_bib47","doi-asserted-by":"crossref","first-page":"873","DOI":"10.7314\/APJCP.2012.13.3.873","article-title":"Expression analysis of MiR-21, MiR-205, and MiR-342 in breast cancer in Iran","volume":"13","author":"Savad","year":"2012","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105188_bib48","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.prosdent.2022.05.019","article-title":"Development and validation of a risk-of-bias tool for assessing in vitro studies conducted in dentistry: The QUIN","volume":"131","author":"Sheth","year":"2024","journal-title":"J. Prosthet. Dent."},{"key":"10.1016\/j.critrevonc.2026.105188_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.899145","article-title":"The role of MIRNAs in the resistance of anthracyclines in breast Cancer: a systematic review","volume":"12","author":"Si","year":"2022","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105188_bib50","first-page":"45","article-title":"Nanoliposomal Delivery of MicroRNA-203 Suppresses Migration of Triple-Negative Breast Cancer through Distinct Target Suppression","volume":"7","author":"Song","year":"2021","journal-title":"NonCoding RNA"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105188_bib51","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.3390\/ijms23052856","article-title":"Nanomedicine-Based Delivery Strategies for breast cancer treatment and management","volume":"23","author":"Tagde","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105188_bib52","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.3390\/ijms23084249","article-title":"Nanoliposomes in cancer therapy: Marketed products and current clinical trials","volume":"23","author":"Tal\u00e9ns-Visconti","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105188_bib53","doi-asserted-by":"crossref","first-page":"6965","DOI":"10.1096\/fj.201801013R","article-title":"Up-regulation of miR-210 induced by a hypoxic microenvironment promotes breast cancer stem cell metastasis, proliferation, and self-renewal by targeting E-cadherin","volume":"32","author":"Tang","year":"2018","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105188_bib54","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13045-023-01468-8","article-title":"Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study","volume":"16","author":"Tassone","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105188_bib55","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/s41416-018-0287-3","article-title":"Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells","volume":"119","author":"Tian","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105188_bib56","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1186\/s13287-025-04667-x","article-title":"MiRNA delivery systems in cancer stem cell therapy: exosomes versus chitosan nanoparticles","volume":"16","author":"Valizadeh-Otaghsara","year":"2025","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.critrevonc.2026.105188_bib57","doi-asserted-by":"crossref","first-page":"113837","DOI":"10.18632\/oncotarget.22985","article-title":"Overexpression of miR-489 enhances efficacy of 5-fluorouracil-based treatment in breast cancer stem cells by targeting XIAP","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2026.105188_bib58","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41417-018-0035-0","article-title":"miR-140-5p inhibits the proliferation and enhances the efficacy of doxorubicin to breast cancer stem cells by targeting Wnt1","volume":"26","author":"Wu","year":"2019","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.critrevonc.2026.105188_bib59","doi-asserted-by":"crossref","first-page":"8773","DOI":"10.2147\/OTT.S188836","article-title":"miR-1 inhibits the proliferation of breast cancer stem cells by targeting EVI-I","volume":"11","author":"Wu","year":"2018","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.critrevonc.2026.105188_bib60","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1186\/s12885-020-07395-y","article-title":"Oncogenic miR-20b-5p contributes to malignant behaviors of breast cancer stem cells by bidirectionally regulating CCND1 and E2F1","volume":"20","author":"Xia","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105188_bib61","doi-asserted-by":"crossref","first-page":"22003","DOI":"10.18632\/oncotarget.15781","article-title":"MiR-519d impedes cisplatin-resistance in breast cancer stem cells by down-regulating the expression of MCL-1","volume":"8","author":"Xie","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105188_bib62","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/mc.23167","article-title":"miR-155 increases stemness and decitabine resistance in triple-negative breast cancer cells by inhibiting TSPAN5","volume":"59","author":"Yang","year":"2020","journal-title":"Mol. Carcinog."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105188_bib63","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.18632\/oncotarget.12284","article-title":"Triple-negative breast cancer: is there a treatment on the horizon?","volume":"8","author":"Yao","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105188_bib64","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1080\/26895293.2021.1934575","article-title":"Circular RNA CDR1as-induced autophagy regulates the proliferation and migration of CD44+\/CD24- phenotype breast cancer stem cells in vitro","volume":"14","author":"Ye","year":"2021","journal-title":"All Life"},{"key":"10.1016\/j.critrevonc.2026.105188_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.reth.2021.01.004","article-title":"miRNA signaling networks in cancer stem cells","volume":"17","author":"Yoshida","year":"2021","journal-title":"Regen. Ther."},{"key":"10.1016\/j.critrevonc.2026.105188_bib66","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.2147\/OTT.S165156","article-title":"Effects of miRNAs on functions of breast cancer stem cells and treatment of breast cancer","volume":"11","author":"Zhang","year":"2018","journal-title":"Onco Targets Ther."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105188_bib67","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3892\/etm.2020.9196","article-title":"MiR-376c-3p modulates the properties of breast cancer stem cells by targeting RAB2A","volume":"20","author":"Zhao","year":"2020","journal-title":"Exp. Ther. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105188_fur1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40291-019-00439-5","article-title":"MicroRNAs, a promising target for breast cancer stem cells","volume":"24","author":"Das","year":"2019","journal-title":"Mol. Diagn. Ther."},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105188_fur2","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","article-title":"Treatment of HCV infection by targeting MicroRNA","volume":"368","author":"Janssen","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105188_fur3","unstructured":"World Cancer Research Fund. (2025). Breast cancer statistics. \u3008https:\/\/www.wcrf.org\/preventing-cancer\/cancer-statistics\/breast-cancer-statistics\/\u3009."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T11:50:55Z","timestamp":1775908255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826000752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":70,"alternative-id":["S1040842826000752"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105188","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic potential of MicroRNAs in targeting breast cancer stem cells: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105188","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105188"}}